Clinical trial · Interventional
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Due to considerations regarding the appropriate therapeutic regimen for these patients.
Summary
Brief summary (as posted)
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Induction chemotherapy | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
| Zalutumumab | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Zalutumumab 8 mg/kg
- interventionNames
- Biological: Zalutumumab
- Drug: Induction chemotherapy
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Progression Free Survival Verified by Imaging Techniques.
- timeFrame
- Until disease progression
- description
- Disease progression was planned to be confirmed using RECIST criteria J Natl Cancer Inst 2000;92:205-16
Secondary outcomes (1)
- measure
- Adverse Events
- timeFrame
- Up to 3 months
- description
- Number of participants reporting at least one adverse event
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * NSCLC stage IIIA-IIIB * Performance status 0 or 1 (Zubrod or WHO Scale) Exclusion Criteria: * Evidence of metastases either in a separate lobe of the lung, or extra thoracic * Patients with high risk of radiation pneumonitis and or compromised lung function * Estimated life expectancy of less than 3 months * Prior chemotherapy for lung cancer * Prior radiotherapy to the chest * Prior surgery with curative intent for lung cancer
References
Publications (0)
Data not yet available